Compare Workiva Inc (WK) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Workiva Inc vs Zoetis Inc — how do they compare? Workiva Inc trades at $73.25 (market cap $4.01B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 7.5× Workiva Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Workiva Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Workiva Inc for 21 Days and Zoetis Inc for 70 Days on average.
| WK | ZTS | |
|---|---|---|
Market Cap | $4.01B | $30.20B |
Volume | 1,301,708 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $93.31 | $147.53 |
52-Week Low | $44.31 | $69.09 |
Typical Hold Time | 21 Days | 70 Days |
Enterprise Value | $3.99B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Workiva (WK) trades at $73.25, up 2.4% with strong bullish technical signals from moving averages. The company shows improving fundamentals with revenue growth from $885M in 2025 to $966M in 2026 and a shift to profitability with net income of $47M. Recent earnings beats and analyst optimism (16 buy ratings) support the positive momentum, though high valuation ratios (P/E 87.73) suggest premium pricing.
Outlook remains positive with consensus price target of $86 offering 17% upside potential. Key risks include elevated valuation metrics and competitive pressures in the regulatory technology space. The company's AI innovations and inclusion in analyst 'top picks' lists provide growth catalysts, but investors should monitor execution against high expectations.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
